Results 121 to 130 of about 522,036 (354)

Macrophage‐Targeted Magnesium Ion‐Nourisher for NLRP3 Inflammasome Inhibition to Enhance Liver Inflammatory Disease Treatment

Advanced Science, EarlyView.
This report describes a nano magnesium nourisher, named MgC@PS, capable of targeted Mg2⁺ delivery to macrophages, effectively suppressing The nuclear factor kappa B (NF‐κB) activation and mitigating NLRP3 inflammasome‐driven pyroptosis in liver inflammation.
Li Wang, Zhuo Yan, Sindhu Yalavarthi, Yusif Abdul‐Rashid, Kiki Parker, Kyle Nowlin, Ethan Li, Jordan Mack, Josephine Wei, Hunter Vu, Zhenquan Jia, Jianjun Wei, Jilong Wang, Kerui Wu   +13 more
wiley   +1 more source

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

BMC Gastroenterology, 2021
Leonardo Ruiz-Casas, Jonathan Evans, Alison Rose, Gabriel Ghizzi Pedra, Alan Lobo, Alan Finnegan, Bu Hayee, Laurent Peyrin-Biroulet, Andreas Sturm, Johan Burisch, Helen Terry, Luisa Avedano, Seb Tucknott, Gionata Fiorino, Jimmy Limdi   +14 more
doaj   +1 more source

Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases

Advanced Science, EarlyView.
Mitochondrial dysfunction is central to metabolic diseases. Nanomedicine offers transformative approaches for restoring function via targeted delivery, responsive release, and multimodal therapy. This review outlines the pathological basis, nanocarrier design, organelle‐specific targeting, recent advances, and future clinical translation challenges ...
Ke Xu, Leyi Wang, Tao Lv, Chen Jin, Qiong Wu, Yongjie Zhou, Gang Xu, Zhenyu Duan, Kui Luo, Jiayin Yang   +9 more
wiley   +1 more source

Protective Effect of Curcumin on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Obese Mice

Korean Journal of Clinical Laboratory Science, 2022
Ulcerative colitis is a disease that causes inflammation in the mucosal or submucosal layer of the colon. Previous studies have reported that obesity increases the prevalence of ulcerative colitis and aggravates the progression.
Ho Park
doaj   +1 more source

6-thioguanine treatment in inflammatory bowel disease: A critical appraisal by a European 6-TG working party [PDF]

, 2006
Recently, the suggestion to use 6-thioguanine (6-TG) as an alternative thiopurine in patients with inflammatory bowel disease (IBD) has been discarded due to reports about possible (hepato) toxicity. During meetings arranged in Vienna and Prague in 2004,
A. Teml, A.A. van Bodegraven, Al Hadithy AF, Artlich A, Bean RHD, Buffet C, C.J.J. Mulder, Carter MJ, Daniel F, De Boer N, de Boer NK, de Boer NK, de Jong D, Derijks LJ, Dervieux T, Dubinsky MC, Ferlitsch A, Fonseca V, Gane E, Gearry RB, H. Vogelsang, Haboubi NY, Herrlinger KR, Herrlinger KR, Herrlinger KR, J. Seiderer, Jones MC, K.R. Herrlinger, Katzka DA, Lilleyman JS, M. Lukas, M. Schwab, Marinaki AM, McBride KL, N.K.H. de Boer, Naber AH, P. Knoflach, Russmann S, Rutgeerts P, S. Almer, S.W. van der Merwe, Sandborn W, Schaeffeler E, Seiderer J, Shastri S, T. Ochsenkühn, Teml A, Teml A, Teml A, Tiede I, van Dieren JM, W. Petritsch, W. Reinisch   +52 more
core   +1 more source

DR5 Governs Compound Exocytosis in Colonic Goblet Cells via TATA‐Box Binding Protein‐Dependent Bestrophin‐2 Transcriptional Regulation

Advanced Science, EarlyView.
DR5 knockout exhibits a thinner colonic mucus layer, leading to mild dysbiosis, increased susceptibility to Citrobacter rodentium invasion, and exacerbated epithelial injury. Mechanistically, DR5 binds transcription factor TBP, which regulates the expression of gene Best2 via its promoter.
Ying Wang, Xinyun Li, Yong Wang, Chuhe Yang, Xiaopei Gao, Ke Zhu, Yihang Ren, Jingxin Li, Chuanyong Liu, Bing Xue   +9 more
wiley   +1 more source

Lifestyle Issues in Inflammatory Bowel Disease – Smoking

Canadian Journal of Gastroenterology, 1994
During the pa t decade, smoking habit has been identified as a major exogenous factor in inflammatory bowel disease (IBD). It is associated not only with the development of the disease but al o with the clinical course in established disease.
Cecilia Benoni
doaj   +1 more source

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

Detecting and managing small bowel Crohn’s disease – capsule endoscopy becoming a first line diagnostic method? [PDF]

, 2011
Small bowel endoscopy is crucial for diagnosing small bowel Crohn’s disease, and capsule endoscopy is complemented by balloon-assisted enteroscopy to take biopsies and by magnetic resonance imaging to visualize enteral and extra-intestinal involvement ...
Albert, Jörg Gerhard, Hausmann, Johannes   +1 more
core   +1 more source

Research Progress on Idebenone in Neurodegenerative Diseases

AGING MEDICINE, EarlyView.
The study not only summarizes the biological properties of Idebenone (IDE), including its role in improving mitochondrial function and antioxidative stress, but also explores its clinical research progress in various neurodegenerative diseases, providing a new perspective for the treatment of these disorders.
Yanqing Zhang, Yanhong Ren, Xiaoran Zhu, Tianhao Liu, Rundong Han, Yuqing Fang, Zhangning Zhao, Fei Mao, Yalin Wang, Xian Li, Xiuhua Li   +10 more
wiley   +1 more source